An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF).

Trial Profile

An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF).

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions; Expanded access
  • Acronyms JUMP
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Jul 2018 Results were announced at the 23rd European Society of Hematology (EHA) 2018, as reported in a Novartis Media release.
    • 04 Jul 2018 Results published in the Novartis Media Release
    • 17 Jun 2018 Results analyzing the impact of baseline patient characteristics and dose on spleen and symptom response in patients with MF in the JUMP study presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top